Medical Doctor Program year 2023 Reported 2019–2023 Source: CMS Open Payments, 2026 publication

Mouhab Aljajeh

Ophthalmology Malta, NY Medical Doctor

NPI 1639338627 CMS profile 210846

658 Malta Ave, Ste 101, Malta, NY 12020

Open in the dashboard

General payments

$1,906

57 records reported · program years 2019–2023

Research payments

$0

Paid to them · None reported · program years 2019–2023

Ownership & investment interest

$0

None reported

Through program year 2023, Mouhab Aljajeh of Malta, NY is reported in the CMS Open Payments database as having received $1,906 across 57 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 58th percentile of Ophthalmology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2023 General $167 2
2022 General $470 16
2021 General $542 10
2020 General $165 8
2019 General $562 21

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Mouhab Aljajeh
  • Ophthalmology median
  • Middle half of Ophthalmology
  • National median

In program year 2025, general payments to Mouhab Aljajeh were reported at $0. Among 13,034 Ophthalmology profiles paid that year, the median was $384 and the middle half received between $136 and $917.

Show as a table
Year Mouhab Aljajeh Ophthalmology median Middle half National median
2019 $562 $258 $104–$655 $163
2020 $165 $126 $45–$321 $114
2021 $542 $205 $76–$534 $132
2022 $470 $266 $100–$678 $149
2023 $167 $308 $117–$745 $160
2024 $0 $340 $127–$846 $164
2025 $0 $384 $136–$917 $169

Breakdown

Who paid General payments · program years 2019–2023
  1. Sight Sciences, Inc. $375 9 payments
  2. Alcon Vision LLC $361 8 payments
  3. Allergan Inc. $277 8 payments
  4. Aerie Pharmaceuticals, Inc. $180 5 payments
  5. Novartis Pharmaceuticals Corporation $176 3 payments
  6. Omeros Corporation $121 1 payment
  7. Bausch & Lomb, a division of Bausch Health US, LLC $110 9 payments
  8. Regeneron Healthcare Solutions, Inc. $95 3 payments
  9. Kala Pharmaceuticals, Inc. $83 3 payments
  10. Mallinckrodt Hospital Products Inc. $33 2 payments
  11. Other $96 6 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2023
  1. Food and Beverage $1,861 56 payments
  2. Gift $45 1 payment
Products named General payments · program years 2019–2023
  1. rocklatan $305 7 payments
  2. rhopressa $247 2 payments
  3. OMNI(R) SURGICAL SYSTEM (US) $208 7 payments
  4. XIIDRA $176 3 payments
  5. OMNI SURGICAL SYSTEM $167 2 payments
  6. Luxor $139 1 payment
  7. Omidria $121 1 payment
  8. EYLEA $95 3 payments
  9. LOTEMAX SM $87 6 payments
  10. INVELTYS $83 3 payments
  11. Other $465 27 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 3 drugs

Part D claims

51

Median for Ophthalmology: 891

Drug cost

$12,498

Median for Ophthalmology: $68,233

Branded share of claims

70.6%

Median for Ophthalmology: 29.7%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Rocklatan Netarsudil Mesylat/Latanoprost Brand 23 $12,027
Dorzolamide-Timolol Dorzolamide Hcl/Timolol Maleat Brand 13 $258
Latanoprost Generic 15 $213

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 18,260 Part D prescribers listed as Ophthalmology; they describe a distribution and say nothing about conduct.

Records

57 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Ophthalmology in New York

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2023

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record